Scancell Lines Up Nasdaq Listing Ahead of Phase III Melanoma Trial
Scancell is preparing a Nasdaq listing as the UK cancer-vaccine developer moves toward a pivotal phase III melanoma trial, putting a new therapeutic vaccine candidate on the watchlist for US dermatol…